Heightened efficacy of combined CPMV IIT and anti-Lymphocyte-activation gene-3 (LAG-3) treatment in a mouse model of melanoma have been observed wherein LAG-3 functions as a next-generation inhibitory immune checkpoint with broad expression across multiple immune cell subsets. The gene discussed is LAG3; the disease is melanoma.